Pharmaceutical

WuXi debates sale of pharma operations as BIOSECURE Act advances

WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.

Oct 6, 2024 - 04:00
WuXi debates sale of pharma operations as BIOSECURE Act advances
WuXi is considering the sale of some US and European operations to mitigate the impact of upcoming restrictions.
Read the original article

Tags:

Previous Article

Editas trades part of Vertex CRISPR therapy licencing rights deal for $57m

Next Article

The benefits of using a nimble platform from phase to phase

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

A new deal aims to ramp up use of AI in rehab care decisions

A new deal aims to ramp up use of AI in rehab care deci...

Jul 20, 2023

Gilead wins patent battle with US government over HIV PrEP drugs

Gilead wins patent battle with US government over HIV P...

May 10, 2023

Subasumstat by Takeda Pharmaceutical for Relapsed Multiple Myeloma: Likelihood of Approval

Subasumstat by Takeda Pharmaceutical for Relapsed Multi...

Jan 9, 2024